IN8bio Appoints Dr. Corinne Epperly to Board of Directors
07 Dezembro 2023 - 10:00AM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today announced the appointment of Corinne Epperly, MD,
MPH, to its Board of Directors.
“Dr. Epperly brings an incredible range of
experience from strategic operations and corporate development to
clinical and commercial readiness at leading organizations such as
CARGO Therapeutics, Bristol Myers Squibb, Iovance Biotherapeutics
and Goldman Sachs. Her prior roles focused on advancing
immuno-oncology and cellular therapies from strategic, clinical,
and commercial perspectives, all of which is directly relevant to
our business,” said William Ho, CEO and co-founder of IN8bio. “We
welcome her to our team and look forward to her insights as we
continue to move toward our mission of achieving Cancer Zero.”
Dr. Epperly will serve on IN8bio’s Compensation
Committee as well as its Science & Technology Committee. She
will work closely with the management team to provide guidance on
strategic, operational, scientific, and clinical matters related to
the Company’s pipeline of gamma-delta T cell therapies. With over
two decades of experience in oncology as a physician and a
scientist, Dr. Epperly uniquely combines her medical expertise with
business and financial acumen. She has spent 15 years in leadership
roles with a successful track record in oncology drug development
and launches.
Before joining IN8bio, Dr. Epperly most recently
served as the Chief Operating Officer of CARGO Therapeutics, where
she was a key player in CARGO’s formation and the advancement of
its next-generation CAR-T cell therapies for cancer patients. Her
prior roles include Senior Vice President, Strategy and Operations
of Iovance Biotherapeutics and leadership roles at Bristol Myers
Squibb, where she played a pivotal role in the launch of OPDIVO®
across multiple indications.
“I am thrilled to be joining IN8bio’s Board of
Directors and contributing to our shared commitment to advance
innovative therapies that can positively impact the lives of cancer
patients,” said Corinne Epperly, MD, MPH. “With the Company’s
recent scientific and clinical updates, it’s an exciting time to
advance these novel therapies for cancer patients. I am honored to
lend my knowledge and experience to help the team realize the
far-reaching potential of IN8bio’s innovative gamma-delta T cell
therapies.”
Dr. Epperly also serves on the board of Sastra
Cell Therapy, a Samsara BioCapital and The Column Group funded cell
therapy startup. Previously she served on the board of AVEO
Oncology until its acquisition by LG Chem in early 2023. Dr.
Epperly holds a Distinguished Bachelor of Arts in Biochemistry and
Biology from the University of Virginia. She earned her Doctorate
of Medicine from the University of North Carolina School of
Medicine and her Masters of Public Health from the University of
North Carolina Gillings School of Global Public Health.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of gamma-delta T cell product candidates for solid and liquid
tumors. Gamma-delta T cells are a specialized population of T cells
that possess unique properties, including the ability to
differentiate between healthy and diseased tissue. IN8bio’s DeltEx
platform employs allogeneic, autologous, iPSC and genetically
modified approaches to develop cell therapies, designed to
effectively identify and eradicate tumor cells.
IN8bio has initiated a Phase 2 trial of INB-400
in GBM at multiple centers across the United States and has two
ongoing Phase 1 trials in solid and hematological tumors, including
INB-200 for GBM and INB-100 for patients with hematologic
malignancies undergoing transplantation. IN8bio also has a broad
portfolio of preclinical programs focused on addressing other
hematological and solid tumor cancers. For more information about
IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking Statements
This press release may contain forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by words such as “aims,” “anticipates,”
“believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,”
“intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will”
and variations of these words or similar expressions that are
intended to identify forward-looking statements, although not all
forward-looking statements contain these words. Forward-looking
statements in this press release include, but are not limited to,
statements regarding the ability of Dr. Epperly’s prior experience
to help the advancement of IN8bio’s business; Dr. Epperly’s ability
to provide guidance on strategic, operational, scientific, and
clinical matters related to the company’s pipeline of gamma-delta T
cell therapies; IN8bio’s ability to advance novel therapies for
cancer patients; and the development and continued progress and
success of IN8bio’s preclinical and clinical trials and programs
and product candidates. IN8bio may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various factors,
including: risks to site initiation, clinical trial commencement,
patient enrollment and follow-up, as well as IN8bio’s ability to
meet anticipated deadlines and milestones; uncertainties inherent
in the initiation and completion of preclinical studies and
clinical trials and clinical development of IN8bio’s product
candidates; the risk that IN8bio may not realize the intended
benefits of its DeltEx platform; availability and timing of results
from preclinical studies and clinical trials; whether the outcomes
of preclinical studies will be predictive of clinical trial
results; whether initial or interim results from a clinical trial
will be predictive of the final results of the trial or the results
of future trials; the risk that trials and studies may be delayed
and may not have satisfactory outcomes; potential adverse effects
arising from the testing or use of IN8bio’s product candidates;
expectations for regulatory approvals to conduct trials or to
market products; IN8bio’s reliance on third parties, including
licensors and clinical research organizations; and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements. These and other
factors are described in greater detail in the section entitled
“Risk Factors” in our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) on November 9, 2023, as
well as in other filings IN8bio may make with the SEC in the
future. Any forward-looking statements contained in this press
release speak only as of the date hereof, and IN8bio expressly
disclaims any obligation to update any forward-looking statements
contained herein, whether because of any new information, future
events, changed circumstances or otherwise, except as otherwise
required by law.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact: Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024